Nipple fluid for breast cancer diagnosis using the nanopore of Phi29 DNA-packaging motor.

Nanomedicine

Center for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Dorothy M. Davis Heart and Lung Research Institute, James Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. Electronic address:

Published: February 2023

Detection of cancer in its early stage is a challenging task for oncologists. Inflammatory breast cancer has symptoms that are similar to mastitis and can be mistaken for microbial infection. Currently, the differential diagnosis between mastitis and Inflammatory breast cancer via nipple aspirate fluid (NAF) is difficult. Here, we report a label-free and amplification-free detection platform using an engineered nanopore of the phi29 DNA-packaging motor with biomarker Galectin3 (GAL3), Thomsen-Friedenreich (TF) binding peptide as the probe fused at its C-terminus. The binding of the biomarker in NAF samples from breast cancer patients to the probe results in the connector's conformational change with a current blockage of 32 %. Utilization of dwell time, blockage ratio, and peak signature enable us to detect basal levels of biomarkers from patient NAF samples at the single-molecule level. This platform will allow for breast cancers to be resolved at an early stage with accuracy and thoroughness.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035634PMC
http://dx.doi.org/10.1016/j.nano.2022.102642DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
nanopore phi29
8
phi29 dna-packaging
8
dna-packaging motor
8
early stage
8
inflammatory breast
8
naf samples
8
breast
5
cancer
5
nipple fluid
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!